Severity of cerebral palsy and incidence of adverse events following botulinum toxin A injections

Karen Bau, C Swinney, Karen Oakley, S O'Flaherty, Simon Paget

Research output: Contribution to conference (non-published works)Abstractpeer-review

Abstract

Background and Objective(s): Botulinum toxin A (BoNT-A) is a well-established treatment for hypertonia in children with cerebral palsy (CP). The incidence of adverse events (AE) following BoNT-A has been estimated as 3.3–7.4%. This study aims to identify if severity of CP correlates with incidence of severe adverse events after BoNT-A.
Original languageEnglish
Pages80-80
Number of pages1
DOIs
Publication statusPublished - 24 Aug 2017
Externally publishedYes
Event71st Annual Meeting of the American Academy for Cerebral Palsy and Developmental Medicine (AACPDM) - Montreal, Montreal, Canada
Duration: 13 Jun 201716 Jun 2017

Conference

Conference71st Annual Meeting of the American Academy for Cerebral Palsy and Developmental Medicine (AACPDM)
Country/TerritoryCanada
CityMontreal
Period13/06/1716/06/17

Fingerprint

Dive into the research topics of 'Severity of cerebral palsy and incidence of adverse events following botulinum toxin A injections'. Together they form a unique fingerprint.

Cite this